VILASTOBART
UNII 8FUE2D4G82

Substance Identification & Data

This profile provides standardized clinical and technical data for Vilastobart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8FUE2D4G82.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2760549-50-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8FUE2D4G82

CAS Registry Number

2760549-50-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VILASTOBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203034

National Cancer Institute reference terminology for clinical and research data.

INN ID

12761

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-226

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vilastobart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VILASTOBART

Common Names & Synonyms

GAMMA1 HEAVY CHAIN HUMANIZED (1-449) (VH (HOMO SAPIENS IGHV1-69*08 (84.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT(8.8.12) (26-33.51-58.97-108)) (1-119) -HOMO SAPIENS IGHG1*01, G1M17,1 CH1 K120, D12, L14, G1V7 CH2 D3, E117 (CH1 K120 (216) (120-217), HINGE 1-15 (218-232), CH2 S3>D(241), I117>E (334) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)), (222-241')-DISULFIDE WITH FUSED PRODOMAIN KAPPA LIGHT CHAIN HUMANIZED (1'-241') (PRODOMAIN (1'-28') FUSED TO V- KAPPA (HOMO SAPIENS IGKV6-21*02 (78.5%) -IGKJ4*01 (100%), CDR-IMGT (5.3.9) (55'-59'.77'-79'.116'-124'))(29'-134') -HOMO SAPIENS IGKC*01, KM3 A45.1 (180'), V101(218') (135'-241')); DIMER (228-228'':231-231'')-BISDISULFIDE

VILASTOBART [INN]

VILASTOBART [USAN]

XTX 101 [WHO-DD]

Systematic Nomenclature

CTLA4 (CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4, CTLA-4, CD152)), HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HUMANIZED (1-449) (VH (HOMO SAPIENS IGHV1-69*08 (84.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT (8.8.12) (26-33.51-58.97-108)) (1-119) -HOMO SAPIENS IGHG1*01, G1M17,1 CH1 K120, D12, L14, G1V7 CH2 D3, E117 (CH1 K120 (216) (120-217), HINGE 1-15 (218-232), CH2 S3>D (241), I117>E (334) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)), (222-241')-DISULFIDE WITH FUSED PRODOMAIN KAPPA LIGHT CHAIN HUMANIZED (1'-241') (PRODOMAIN (1'-28') FUSED TO V- KAPPA (HOMO SAPIENS IGKV6-21*02 (78.5%) -IGKJ4*01 (100%), CDR-IMGT (5.3.9) (55'-59'.77'-79'.116'-124')) (29'-134') -HOMO SAPIENS IGKC*01, KM3 A45.1 (180'), V101 (218') (135'-241')); DIMER (228-228'':231-231'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

SYS

IMMUNOGLOBULIN G1 (241-ASPARTIC ACID,334-GLUTAMIC ACID), ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-RATTUS NORVEGICUS MONOCLONAL XTX101 .GAMMA.1-CHAIN), DISULFIDE WITH PRODOMAIN PROTEIN (SYNTHETIC MASKING MOIETY AND PROTEASE-CLEAVABLE MOIETY) FUSION PROTEIN WITH HUMAN-RATTUS NORVEGICUS MONOCLONAL XTX101 .KAPPA.-CHAIN, DIMER

SYS